Valuation: TScan Therapeutics, Inc.

Market Cap 59.78M 52.24M 48.21M 44.44M 83.76M 5.76B 85.62M 576M 227M 2.82B 225M 220M 9.71B P/E 2026 *
-1.05x
P/E 2027 * -0.99x
Enterprise Value -39.08M -34.16M -31.52M -29.05M -54.76M -3.76B -55.97M -377M -148M -1.84B -147M -144M -6.35B EV / Sales 2026 *
-5.17x
EV / Sales 2027 * -1.92x
Free-Float
93.27%
Yield 2026 *
-
Yield 2027 * -
06-22 TScan Therapeutics Presents Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation CI
06-22 TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment MT
06-03 Cellares and TScan Therapeutics Inc. Announce Agreement To Evaluate Automated Manufacturing Of TSC-101 CI
05-06 TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-02 TScan Therapeutics, Inc. Announces Executive Changes, Effective April 10, 2026 CI
03-04 TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
02-26 TScan Therapeutics completes enrollment in cohort C of Phase 1 Alloha(TM) trial RE
02-26 TScan Therapeutics, Inc. Completes Enrollment in Cohort C of Phase 1 AlloHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A03 CI
12-19 TScan Therapeutics, Inc.(NasdaqGM:TCRX) dropped from NASDAQ Biotechnology Index CI
12-07 TScan Therapeutics Announces Positive Updated Data from the AlloHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition CI
11-14 Morgan Stanley Downgrades TScan Therapeutics to Equalweight From Overweight MT
11-12 TScan Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-12 TScan Therapeutics Q3 revenue jumps RE
1 day+1.80%
1 week-16.07%
Current month-6.66%
1 month+1.66%
3 months-23.13%
6 months-19.04%
Current year-8.52%
1 week 0.88
Extreme 0.876
1.1
1 month 0.83
Extreme 0.8251
1.28
Current year 0.83
Extreme 0.8251
1.47
1 year 0.83
Extreme 0.8251
2.57
3 years 0.83
Extreme 0.8251
9.69
5 years 0.83
Extreme 0.8251
14.71
10 years 0.83
Extreme 0.8251
14.71
Manager TitleAgeSince
Chief Executive Officer 56 28/03/2023
Director of Finance/CFO 57 29/01/2024
Chief Tech/Sci/R&D Officer 50 08/04/2024
Director TitleAgeSince
Director/Board Member 68 23/03/2021
Director/Board Member 56 24/05/2023
Chairman 55 12/06/2024
Date Insider Type Main position Quantity % Market Cap.
5/20/26 A Free

Director

67,000 0.1200%
5/20/26 A Free

Director

67,000 0.1200%
5/20/26 A
Baker Bros. Advisors LP
FreeCompany 134,000 0.2400%
Change 5-day change 1-year change 3-year change Capi.($)
+1.80%-16.07%-51.60%-57.45% 59.78M
-7.17%-4.39%+45.51%+79.00% 52.1B
+0.24%-1.54%+53.22%+71.85% 53.83B
+0.80%-6.31%+3.98%+423.29% 23.48B
-0.09%-0.01%-17.62%-14.67% 23.13B
-5.95%-2.58%+30.67%-9.58% 19.36B
-1.14%+0.03%+31.57%-30.42% 17.56B
-5.16%-7.00%+168.44%+306.37% 15.2B
-6.91%-5.83%+26.53%+636.97% 14.83B
+0.43%-1.03%+24.63%+191.40% 14.06B
Average -2.32%-3.97%+31.53%+159.67% 23.36B
Weighted average by Cap. -2.80%-2.36%+40.10%+144.05%

Financials

2026 *2027 *
Net sales 7.56M 6.6M 6.09M 5.62M 10.59M 728M 10.82M 72.84M 28.65M 356M 28.38M 27.76M 1.23B 7.81M 6.82M 6.3M 5.8M 10.94M 752M 11.18M 75.25M 29.6M 368M 29.32M 28.68M 1.27B
Net income -115M -101M -92.79M -85.53M -161M -11.08B -165M -1.11B -436M -5.43B -432M -423M -18.68B -125M -109M -101M -92.78M -175M -12.02B -179M -1.2B -473M -5.89B -469M -458M -20.27B
Net Debt -98.87M -86.4M -79.73M -73.49M -139M -9.52B -142M -953M -375M -4.66B -371M -363M -16.05B -74.76M -65.33M -60.28M -55.57M -105M -7.2B -107M -721M -283M -3.53B -281M -275M -12.14B
Logo TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
Employees
139
Date Price Change Volume
17/07/26 $0.9148 +1.80% 143,982
16/07/26 $0.8986 -2.65% 651,704
15/07/26 $0.9231 -0.74% 473,755
14/07/26 $0.9300 -9.71% 1,640,085
13/07/26 $1.030 -5.50% 1,152,419
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.9148USD
Average target price
6.000USD
Spread / Average Target
+555.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRX Stock